Table 1.
Pre-treatment | Intervention | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
NC | Autoclaved water | |||||||||||||||
PC | Autoclaved water | LPS in autoclaved water | ||||||||||||||
TL | 1% IMD in autoclaved water | LPS and 1% IMD in autoclaved water | ||||||||||||||
TM | 2.5% IMD in autoclaved water | LPS and 2.5% IMD in autoclaved water | ||||||||||||||
TH | 5% IMD in autoclaved water | LPS and 5% IMD in autoclaved water |
Note: Treatment groups are referred to as follows: NC (negative control), PC (positive control), TL (low treatment dose), TM (medium treatment dose), and TH (high treatment dose). All mice received Teklad Global 14% mouse maintenance diet from Envigo for the duration of the trial. Throughout the trial, mice in the NC and PC groups received autoclaved water, while mice in the TL, TM, and TH groups received 1%, 2.5%, and 5% isomaltodextrin (IMD) in autoclaved water, respectively. Following the pre-treatment period, LPS was added to the drinking water at the beginning of week 5 in a dosage of 300 μg lipopolysaccharide (LPS) (kg body weight)/day to mice in the PC, TL, TM, and TH groups to induce chronic low-grade inflammation.